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Abstract
Background: It has been recently demonstrated that in Frontotemporal Lobar Degeneration
(FTLD) memory deficits at presentation are commoner than previously thought. Apolipoprotein E
(ApoE) genotype, the major genetic risk factor in sporadic late-onset Alzheimer Disease (AD),
modulates cerebral perfusion in late middle-age cognitively normal subjects. ApoE ε4 homozygous
have reduced glucose metabolism in the same regions involved in AD.
The aim of this study was to determine whether ApoE genotype might play a key-role in influencing
the cerebral functional pattern as well as the degree of memory deficits in FTLD patients.
Methods: Fifty-two unrelated FTLD patients entered the study and underwent a somatic and
neurological evaluation, laboratory examinations, a brain structural imaging study, and a brain
functional Single Photon Emission Tomography study. ApoE genotype was determined.
Results: ApoE genotype influenced both clinical and functional features in FTLD. ApoE ε4-carriers
were more impaired in long-term memory function (ApoE ε4 vs. ApoE non ε4, 6.3 ± 3.9 vs. 10.1
± 4.2, p = 0.004) and more hypoperfused in uncus and parahippocampal regions (x,y,z = 38,-6,-20,
T = 2.82, cluster size = 100 voxels; -32,-12,-28, T= 2.77, cluster size = 40 voxels).
Conclusion: The present findings support the view that ApoE genotype might be considered a
disease-modifying factor in FTLD, thus contributing to define a specific clinical presentation, and
might be of relevance for pharmacological approaches.
Background
Frontotemporal Lobar Degeneration (FTLD) is a complex
neurodegenerative syndrome whose broad phenotype is
characterised by personality changes, behavioural distur-
bances, impairment in language, and in executive func-
tions [1].
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Memory deficits are not considered prominent character-
istics at disease onset, but more recent studies demon-
strated that amnesia at presentation in pathologically
proved FTLD cases is commoner than previously thought
[2]. Notwithstanding, the underlying basis of such impair-
ment is still unexplained.
Apolipoprotein E (ApoE) is established as the major
genetic risk factor in sporadic late-onset Alzheimer Dis-
ease (AD), which is mainly characterised by memory
impairment [3]. Moreover, it has been demonstrated that
ApoE genotype modulates cerebral perfusion in late mid-
dle-age cognitively normal subjects, ApoE ε4 homozygous
having reduced glucose metabolism in the same regions
involved in AD [4].
Based on these observations, we hypothesised that ApoE
genotype might play a key-role in influencing the cerebral
functional pattern as well as the degree of memory deficits
in FTLD patients. To this aim, FTLD patients were
enrolled, ApoE genotype defined, and neuropsychological
standardized assessment as well as Single Photon Emis-
sion Tomography (SPECT) cerebral perfusion patterns
assessed.
Methods
Subjects
This is a cross-sectional study of patients consecutively
recruited from a large sample assessed at the Centre for
Aging Brain and Neurodegenerative Diseases, University
of Brescia, Italy.
All patients fulfilled international consensus criteria for
FTLD [5-7]. In keeping with other studies, we retain the
term FTLD as a general super-ordinate label with a subse-
quent subdivision into five major clinical subtypes : 1.
Behavioural or frontal variant FTD (fvFTD) [7], 2. Seman-
tic Dementia (SD) [7], 3. Progressive Non-fluent Aphasia
(PNFA) [7], 4. Progressive Supranuclear Palsy (PSP) [6],
and 5. Corticobasal Degeneration (CBD) [5].
All subjects performed a somatic and neurological evalu-
ation, laboratory examinations, a brain structural Mag-
netic Resonance Imaging study, and a brain functional
SPECT study. ApoE genotype was determined. Thirty-two
out of 52 patients (60%) performed cerebrospinal fluid
(CSF) Tau, Phospho-Tau and Abeta dosage to further con-
firm FTLD diagnosis, being Abeta dosage within the nor-
mal range and thus further excluding other kind of
dementia, i.e. AD.
The diagnostic assessment included a review of full medi-
cal history, a semistructured neurological examination,
including motor subscale of Unified Parkinson Disease
Rating Scale, and a complete mental status evaluation by
two independent and experienced neurologists; only
patients with full consensus agreement by both neurolo-
gists were enrolled.
Global cognitive function assessment was made according
to a standardized battery, including the Mini-Mental State
Examination (MMSE) [8]. The neuropsychological assess-
ment was made with the following tests: Raven Colored
Progressive Matrices [9], Controlled Oral Word Associa-
tion Test and Category Fluency [10], Clock Drawing Test
[11], Rey Complex Figure Copy and Recall [12], Story
Recall Test [13], Digit Span [14], Trail Making Test A and
B [15], Token Test [16], and De Renzi Imitation Test [17].
Instrumental Activities of Daily Living (IADL) [18], and
Basic Activities of Daily Living (BADL) [19] were assessed
as well. Behavioural and psychiatric disturbances were
evaluated by Neuropsychiatry Inventory (NPI) [20], and
Frontal Behavioral Inventory (FBI) [21].
Stringent exclusion/inclusion criteria were applied, as fol-
lows: a) cerebrovascular disorders, previous stroke, hydro-
cephalus, and intra-cranial mass, documented by MRI; b)
a history of traumatic brain injury or another neurologic
disease; c) another extrapyramidal syndrome (e.g. Parkin-
son disease, Lewy Body Disease, Vascular Parkinsonism,
Multiple System Atrophy), according to current clinical
criteria; d) significant medical problems; e) major depres-
sive disorder, bipolar disorder, schizophrenia, substance
use disorder, or mental retardation.
Inclusion criteria: a) mild cognitive decline (Mini-Mental
State Examination, MMSE ≥18), to avoid confounds in
functional data analysis; b) evidence of frontotemporal
hypoperfusion in single subject analysis, excluding sub-
jects with temporo-parietal involvement mimicking AD
pattern; c) CSF Abeta levels>800 pg/ml, when available.
For brain functional data comparisons, a group of healthy
subjects (n = 15, mean age ± SD = 56.3 ± 15.4) were
recruited, and underwent a brain SPECT study.
All participants were made fully aware about the aims of
the research and the signature of an informed consent was
sought from all subjects. The work was conducted in
accordance with local clinical research regulations and
conformed to the Helsinki Declaration.
ApoE genotype analysis
Genomic DNA was extracted from blood samples accord-
ing to standard procedures. Genetic variation at the ApoE
locus was determined by restriction isotyping using
FTLDR amplification and subsequent digestion with Hha
I  (New England Biolabs). Clinical diagnosis and SPECT
analysis were performed in blind to ApoE genotype.BMC Neurology 2006, 6:31 http://www.biomedcentral.com/1471-2377/6/31
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99mTc-ECD SPECT acquisition and processing
Subjects were administered an intravenous injection of
1110 MBq 99mTc-ECD (ethylcysteinate dimer, Neurolite,
Bristol-Myers Squibb Pharma), and were imaged a dual-
head rotating gamma camera (VG MILLENIUM GE),
according with European procedure guidelines [22].
Basic image processing and voxel-based data analyses
were performed by SPM02 routines (Wellcome Depart-
ment of Cognitive Neurology, London, UK) implemented
in MATLAB 6.1 (Mathworks, Sherborn, MA) [23]. SPECT
images were spatially normalized by affine 12-parameter
transformation onto a SPECT template conforms to the
Talairach and Tournoux space. Normalized images were
represented on a 79 × 95 × 68 matrix with 2 × 2 × 2 mm
voxel size. To account for individual variability in struc-
ture-function relationships, an isotropic Gaussian filter
was used to smooth the spatially normalized SPECT
images with a FWHM of 8 mm.
Statistical analysis
Differences between demographic and clinical character-
istics according to ApoE genotype were evaluated by
Mann-Whitney test and Chi-Square test, as indicated.
Results are expressed as percentage or mean ± Standard
Deviation. The significant level was set at p < 0.05.
In regard to SPECT data, global differences in the distribu-
tion of the tracer's uptake and age effect on it were covari-
ated out for all voxels [9]. Comparisons across the
different groups were made using t-statistics with appro-
priate linear contrasts. Threshold was set at p < 0.01 (min-
imum cluster size = 40 voxels).
Results
Subject characteristics
Fifty-five patients with the clinical diagnosis of FTLD
entered the study from March 2003 through April 2005.
Among them, three were subsequently excluded to avoid
confounds: one because of SPECT perfusion pattern
involving temporo-parietal region and cingulate areas,
and two because of low CSF Abeta and high CSF Tau lev-
els, thus resembling AD pattern.
Fifty-two unrelated FTLD patients were finally included
(23 fvFTD, 3 SD, 2 PNFA, 14 PSP, 10 CBD). Overall, FTLD
patients showed mild impairment (MMSE = 25.0 ± 4.1).
fvFTD showed behavioural disturbances, SD and PNFA
were characterized by language deficits, whilst PSP and
CBD had visuo-spatial impairment.
ApoE genotype and patients' characteristics
Seventeen FTLD patients (32.7%) carried at least one
ApoE ε4 allele (9/23 fvFTD, 2/3 SD, 1/2 PNFA, 3/14 PSP,
and 2/10 CBD).
The whole FTLD patient group was divided into two sub-
groups, according to the presence (ApoE ε4+) or the
absence (ApoE ε4-) of ApoE ε4 allele. Demographic and
clinical characteristics of ApoE ε4- and ApoE ε4+ patients
are reported in Table 1. The two subgroups neither dif-
fered for global cognitive impairment or for IADL or
BADL scores. ApoE ε4+ carriers showed worse perform-
ances in Short Story recall compared to ApoE ε4- (6.3 ±
3.9 vs. 10.1 ± 4.2, p = 0.004). Raven Colored Progressive
Matrice scores were worse in ApoE ε4+ carriers, but the
performance was within the normal range in both sub-
groups (ApoE ε4+ vs. ApoE ε4-, 19.0 ± 7.0 vs. 24.6 ± 5.5,
p = 0.003).
Perfusion pattern according to ApoE genotype
The cerebral perfusion assessment in the whole FTLD
group as well as in ApoE ε4- and in ApoE ε4+ FTLD sub-
groups revealed a significant frontotemporal involvement
compared to controls (data not shown).
The direct comparison of the perfusion pattern between
ApoE ε4+ vs. ApoE ε4- demonstrated a significant bilateral
hypoperfusion in uncus and in parahippocampal gyrus
(x,y,z = 38,-6,-20, T = 2.82; -32,-12,-28, T = 2.77, see Fig.
1 and Table 2) and in medial frontal cortex (-12,12,-12, T
= 3.48) in the former group. Notably, in ApoE ε4+ carriers
the typical AD pattern, involving posterior parietal
regions, was not found.
When the opposite comparison was considered, and the
greater hypoperfusion in ApoE ε4- vs. ApoE ε4+ was eval-
uated, no voxels above the threshold were found.
In order to exclude the effect of clinical endophenotypes
in determining the hypoperfusion pattern, the clinical
diagnoses (fvFTD, SD, PNFA, PSP and CBD) were intro-
duced as nuisance variable in the analysis, and the results
were confirmed. Thus, we concluded that the SPECT
hypoperfusion pattern was not due to a specific clinical
endophenotype, but only to ApoE genotype.
Discussion
The present study demonstrates that in a large series of
mildly affected FTLD patients, ApoE ε4+ allele can influ-
ence the phenotypic expression, accounting for a greater
susceptibility to uncus and parahippocampal functional
impairment. Indeed, this functional pattern is associated
with worse performances in test tapping long term mem-
ory functions.
It has been recently highlighted that FTLD may be charac-
terised by memory impairment, but the possible genetic
determinants of the so called amnestic FTLD have not
been identified yet [2]. The autopsy-proven evidence of
amnesic deficits in FTLD has suggested that pathologiesBMC Neurology 2006, 6:31 http://www.biomedcentral.com/1471-2377/6/31
Page 4 of 6
(page number not for citation purposes)
mainly characterised by memory impairment, such as AD,
could share the same genetic risk factors.
In AD, the role of ApoE genotype is well established [24],
and it has been recently demonstrated that ApoE genotype
modifies the phenotype in AD patients, the lack of ApoE
ε4 directing away the pathological process from medial
temporal structures [4].
ApoE genotype affects not only AD, but it may also cogni-
tive performances in normal aging, ε4 allele-carriers
showing altered memory-related cognitive processing
[25]. Furthermore, cross-sectional positron emission tom-
ography studies found that cognitively normal carriers of
the ApoE ε4 allele have abnormally low measurements of
the cerebral metabolic rate for glucose in the same regions
as patients with AD.
Hypoperfusion pattern in Frontotemporal Lobar Degeneration ApoE ε4+ compared to ApoE ε4- carriers: bilateral hippocam- pal structure involvement Figure 1
Hypoperfusion pattern in Frontotemporal Lobar Degeneration ApoE ε4+ compared to ApoE ε4- carriers: 
bilateral hippocampal structure involvement. The direct comparison of the perfusion pattern between Apolipoprotein 
(ApoE) ε4+ vs. ApoE ε4- demonstrated a significant bilateral hypoperfusion in uncus and in parahippocampal gyrus. Talairach 
and Tournoux coordinates. Coronal slices y = -8 to -13, axial slice z = -24,p < 0.01, T > 2.41, minimum cluster size = 40 voxels. 
Functional patterns superimposed to standard T1 weighted MRI.
Table 1: Demographic and clinical characteristics according to Apolipoprotein E genotype.
Variable ApoE ε4- (n = 35) ApoE ε4+ (n = 17) Normal data^ p‡
Age, years 67.1 ± 9.3 68.0 ± 6.9 - .73
Gender, female% 51.4% 64.7% - .37†
Education, years 7.7 ± 4.2 6.9 ± 2.7 - .99
Family History, % 17.1 17.6 - .88
Age at onset, years 64.6 ± 8.8 65.0 ± 6.9 - .96
Estimated disease duration, years 2.6 ± 2.2 2.3 ± 1.2 - .94
MMSE 25.3 ± 3.9 24.4 ± 4.5 24 .54
UPDRS-III 14.7 ± 11.4 10.6 ± 10.9 0 .15
IADL, lost functions 1.2 ± 1.9 2.2 ± 2.2 0 .16
BADL, lost functions 0.6 ± 1.1 0.7 ± 1.1 0 .33
Short Story 10.1 ± 4.2 6.3 ± 3.9 7.5 .004
Rey Figure, copy 27.3 ± 6.7 23.7 ± 9.2 29 .15
Rey Figure, recall 12.5 ± 5.5 10.9 ± 7.5 15 .21
Raven Coloured Matrices 24.6 ± 5.5 19.0 ± 7.0 17.5 .003
Verbal Fluency 25.1 ± 10.7 20.6 ± 10.4 16 .13
Set Test 31.0 ± 9.3 26.6 ± 9.6 24 .13
Digit Span 5.6 ± 1.4 5.4 ± 1.7 3.75 .70
Token Test 30.2 ± 4.3 27.1 ± 5.4 29 .06
Trail Making A, ES = 0 or 1 41.0% 66.0% >1 .48†
Trail Making B, ES = 0 or 1 50.0% 73.0% >1 .44†
De Renzi Imitation Test 64.3 ± 12.2 66.1 ± 9.0 62 .94
ApoE: Apolipoprotein E; MMSE: Mini-Mental State Examination; UPDRS: Unified Parkinson Disease Rating Scale; IADL: Instrumental Activities of 
Daily Living; BADL: Basic Activities of Daily Living; ES: Equivalent Score. Neuropsychological test scores were corrected for age and education; ^ 
defined according to available Italian normative data. ‡ Mann-Whitney test; † Chi-Sqare test. Results are expressed as percentage or mean ± 
Standard Deviation. The significant level was set at p < 0.05.BMC Neurology 2006, 6:31 http://www.biomedcentral.com/1471-2377/6/31
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No definite genetic risk factor of non-monogenic FTLD
has been identified yet. Although the role of the ε4 allele
of ApoE has been well established in AD, studies of ApoE
allele distribution in patients with FTLD have produced
variable results. Literature data on the role of ApoE geno-
type as a risk factor for FTLD development are controver-
sial. Some studies have reported an increased frequency of
the ApoE ε4 allele in FTLD; others have found no relation-
ship between ApoE genotype and the risk of FTLD devel-
opment [26-31]. Our results suggest higher ApoE ε4 allele
frequency in FTLD (39.1%) compared to the reported
incidence in healthy control subjects.
Notwithstanding, data on a possible modulating effect of
ApoE genotype on functional and neuropsychological fea-
tures have not been available yet. The data of the present
work, if replicated in larger studies with neuropathologi-
cal confirmation, may have implications for our under-
standing of the pathogenesis of FTLD and factors
influencing the regional predilection. The fact that the
ApoE  ε4 genotype in our patients was associated with
greater hippocampus hypoperfusion suggests the exist-
ence of common ApoE-related pathways involved in the
development of different clinical FTLD subtypes.
Conclusion
Our study carried out in a group of patients from the same
geographical area and well characterized from the neu-
ropsychological, neurological and imaging point of view
suggests that ApoE genotype might be considered a dis-
ease-modifying factor in FTLD, thus contributing to
define a specific clinical presentation.
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